Diagnostic testing and precision medicine by Castle Biosciences
Castle Biosciences unveils findings from three Barrett Esophagus studies at ACG 2026
Castle Biosciences announced it will present new data from three studies evaluating its TissueCypher Barrett Esophagus test at the American College of Gastroenterology 2026 Annual Scientific ...
Castle Biosciences study finds TissueCypher Barrett Esophagus Test led to 90 percent change in clinician recommendations
Castle Biosciences has announced new research showing its TissueCypher Barrett Esophagus Test prompted clinicians to alter their management recommendations in 90 percent of cases involving ...
Castle Biosciences research finds patient demand for molecular testing in atopic dermatitis treatment
Castle Biosciences has announced the publication of a new study examining the experiences of patients with atopic dermatitis in achieving their treatment goals. The study reveals that patients ...
Castle Biosciences opens new laboratory and office facility in Scottsdale Arizona
Castle Biosciences has opened a new laboratory and office facility in Scottsdale, Arizona. The company plans to mark this milestone with a grand opening celebration at 8667 E. Hartford Drive on ...
Multi center study supports Castle Biosciences DecisionDx SCC test accuracy
Castle Biosciences announced the publication of a multi-center study in the Journal of the American Academy of Dermatology validating the integrated DecisionDx-SCC test result (i40-GEP) for ...
Castle Biosciences begins dual listing on Nasdaq Texas as CSTL expands presence
Castle Biosciences has commenced trading its common stock on Nasdaq Texas, marking a significant expansion in its market presence. The company, which maintains its primary listing on The Nasdaq ...
Castle Biosciences lays out new diagnostic innovation roadmap at Future Biotech Expo
Castle Biosciences took the stage at the Future Biotech Expo 2026, where Dr. Hillary Caruso presented new directions in precision healthcare. Dr. Caruso, a leading scientist with Castle ...
Castle Biosciences gains approval for dual listing on Nasdaq Texas
Castle Biosciences has received approval to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. The company will maintain its primary listing on The ...
Greater Phoenix bioscience alliances drive Castle Biosciences transformation
Castle Biosciences attributes its growth from a small startup to a diagnostics company to the support of the Greater Phoenix bioscience community. Company co-founder and COO Kristen Oelschlager ...
Castle Biosciences revenue reaches 103.5 million as core test volume jumps 32 percent in Q2 2026
Castle Biosciences reported financial results for the second quarter ended June 30, 2026. The company posted revenue of 103.5 million dollars for the quarter. Test volumes of its core products, ...
July 30 set for Castle Biosciences Q2 2026 earnings webcast
Castle Biosciences announced it will publish its financial results for the second quarter of 2026 and host a webcast on Thursday, July 30 at 4:30 pm ET. Investors and analysts can access webcast ...
Castle Biosciences prioritizes people across patients, clinicians, and employees
Castle Biosciences is placing a strategic focus on its people, spanning patients, clinicians, employees, and investors. The company invited team members such as Senior Area Manager Melissa ...
Castle Biosciences celebrates Frank Stokes win at Houston Business Journal CFO Awards
Castle Biosciences Chief Financial Officer Frank Stokes has received a CFO Award from the Houston Business Journal, recognizing him as one of the region's top financial executives. The accolade ...
Castle Biosciences TissueCypher clinical test orders surpass 100,000 milestone
Castle Biosciences announced that clinical test orders for its TissueCypher Barrett esophagus test have surpassed the 100,000 mark. TissueCypher is an AI-driven precision medicine platform aimed ...
Castle Biosciences recognized for driving progress in global healthcare with AdvanceAD-Tx accolade
Castle Biosciences has secured the Genomics Innovation Award in the 10th annual MedTech Breakthrough Awards for its AdvanceAD-Tx test. The MedTech Breakthrough Awards program honors ...
Castle Biosciences to present new Mayo Clinic research on TissueCypher test at Digestive Disease Week
Castle Biosciences will present new research developed in partnership with Mayo Clinic at Digestive Disease Week in Chicago. The studies, featured in two poster sessions, focus on the role of the ...
Laboratory teams drive progress in skin cancer diagnostics at Castle Biosciences
Castle Biosciences is recognizing its laboratory professionals during Lab Week for their critical role in developing innovative diagnostic tests. The company credits its laboratory teams with ...
